U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07514429) titled 'Regorafenib After Failure of Lenvatinib in Patients With Unresectable HCC: The RELEVANT-HCC Trial' on March 24.
Brief Summary: The purpose of this clinical trial is to evaluate the efficacy and safety of regorafenib as a subsequent therapy for patients with hepatocellular carcinoma (HCC) who have failed prior lenvatinib treatment. This investigational study aims to assess the therapeutic benefits and safety profile of regorafenib in patients whose disease has progressed following the use of lenvatinib, a targeted therapy for hepatocellular carcinoma
Study Start Date: March 15
Study Type: INTERVENTIONAL
Condition:
Carcinoma, Hepa...